Ferring’s Nocdurna Nixed By FDA Panel, But Gets Multiple Paths Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members recommend Ferring conduct new pre-approval study to demonstrate clinical meaningful benefit of nocturia treatment, offering up variety of possible study designs.
You may also be interested in...
Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug
Serenity's SER120 should be held to the same efficacy standards as Ferring's Nocdurna, which the agency has declined to approve three times, citizen petition says.
Allergan Nasal Spray For Frequent Nighttime Urination Faces Review Hurdles
Advisory committee will weigh in on desmopressin as FDA questions broad indication and says clinical meaningfulness of treatment effects for Serenity Pharmaceuticals/Allergan’s product vs. placebo are unclear.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.